Key Highlights

  • Argent BioPharma granted a 10-year exclusive worldwide licence covering four proprietary cannabis genotypes to Thai Phytomed International.
  • Argent retains ownership of the underlying genetics and the associated intellectual property.
  • The company will receive a 15% Royalty on profits from commercialisation of the licensed genetics.
  • Thai Phytomed will fund commercialisation and obtain the regulatory and operational approvals required in each market.

Argent BioPharma Ltd (ASX:RGT) announced on 27 October 2026 that it has entered into an exclusive worldwide licensing agreement with Thai Phytomed International Co., Ltd. (TPI) for the commercial development of four cannabis genotypes held within its group. The announcement describes the deal as part of a strategy to extract value from non-core legacy cannabis Assets while focusing internal resources on pharmaceutical development, immune modulation and anti-inflammatory therapeutics.

Scope of the Licence

Under the agreement, TPI receives exclusive worldwide rights to cultivate, propagate, process, extract, manufacture, market, distribute, sell, Import and export the licensed genetics and products derived from them. These include flower, extracts and cannabinoid active pharmaceutical ingredients, subject to regulatory requirements in each market. The initial term is 10 years and can be renewed for a further 10 years on the same terms through written confirmation from both parties.

The four genotypes are MXC-THC-10/3, MXC-THC-81/5, MXC-THC-40/3 and MXC-THC-40/2. The announcement states that the licence is not a sale or transfer of ownership, and that the underlying genetics and intellectual property remain with Argent BioPharma (UK) Ltd, which is wholly owned by Argent BioPharma Limited. Argent may continue to use the genetics for internal pharmaceutical research and development.

The licence covers four genotypes that the company says are owned within its group, and the agreement is limited to the commercial rights described in the announcement. Argent said it will continue to use the genetics for internal pharmaceutical research, which means the company keeps access to the genetic material while TPI holds the commercial rights during the term.

Royalty and Funding Structure

Argent will receive a royalty equal to 15% of profits generated from commercialisation of the licensed genetics. Royalties will be calculated quarterly and will apply to sales made directly by TPI, through TPI-controlled operating entities and through permitted sublicensing arrangements.

TPI is responsible for funding commercial development and for obtaining and maintaining cultivation, manufacturing, quality, import and export approvals. Argent may terminate the licence if no commercial sale of licensed products has been made within 24 months after delivery of the licensed genetic material. The agreement does not include rights to CannEpil, CimetrA, the company's other pharmaceutical products, clinical dossiers, formulations or drug delivery technologies.

Context Within the Company's Portfolio

The announcement places the licence within Argent's wider strategy of monetising its historical cannabis asset base through capital-efficient arrangements. The company said the transaction is intended to convert legacy assets into royalty revenue, while its internal scientific and financial resources remain directed to its pharmaceutical portfolio.

The announcement describes Argent's pharmaceutical portfolio as its internal focus, with work on immune modulation and anti-inflammatory therapeutics. The company identified the licence as a way of directing its scientific and financial resources toward that work while the legacy cannabis assets generate royalty income under the agreement.

Risks and Points to Watch

Royalty income under the agreement depends on TPI's ability to fund commercialisation and to obtain approvals in each market, both of which sit outside Argent's control. The agreement also allows Argent to terminate if no commercial sale has been made within 24 months of delivery of the genetic material, which sets a timeframe for commercial progress.

Future announcements may cover the first commercial sales under the licence, any sublicensing activity and the progress of the company's pharmaceutical development programmes, which the company has said remain its internal priority.

The licence structure leaves Argent's internal pharmaceutical portfolio unchanged, and the agreement excludes its other pharmaceutical products, clinical dossiers, formulations and drug delivery technologies. The company's statement that the arrangement does not transfer ownership means the four genotypes can still be used by Argent internally, while TPI operates within the licensed scope for the duration of the agreement.

Final Word

The licence transfers commercial rights and the associated cost of market development to Thai Phytomed while leaving ownership of the genetics with Argent. Royalty income will depend on the commercial performance of the licensed products, which the announcement says TPI will fund and pursue. The company's next updates are likely to address the timing of first sales and the regulatory steps in individual markets.